A novel brachytherapy and chemotherapy integrated ureteral stent: In vitro and in vivo study.

ABSTRACT: Ureteral carcinoma remains a major clinical challenge and requires effective localized treatment. Here, we report a novel ¹²⁵I seed brachytherapy (ISB) and doxorubicin (DOX) chemotherapy integrated ureteral stent (IUS), which enables simultaneous urinary drainage and chemoradiotherapy. This study was divided into three parts. First, ISB and DOX significantly reduced T24 cell viability and inhibited migration and invasion in an in vivo study (p < 0.01). Second, a T24 xenograft mouse model demonstrated that the (DOX + ISB) group exhibited greater tumor suppression than the DOX (p = 0.08) and ISB (p = 0.02) groups, with decreased Ki-67 and Bcl-2 expression and increased apoptosis (all p < 0.01) in an in vitro study. Third, the IUS was successfully implan

SUBMITTER: Yang X 

PROVIDER: S-EPMC12617561 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature